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Purpose: Stereotactic body radiation therapy (SBRT) is increasingly utilized as primary
treatment for clinically localized prostate cancer. While acute post-SBRT urinary symptoms
are well recognized, the late genitourinary toxicity of SBRT has not been fully described.
Here, we characterize the clinical features of late urinary symptom flare and recommend
conservative symptom management approaches that may alleviate the associated bother.
Methods: Between February 2008 and August 2011, 216 men with clinically localized
prostate cancer were treated definitively with SBRT at Georgetown University Hospital.
Treatment was delivered using the CyberKnife with doses of 35–36.25 Gy in five frac-
tions. The prevalence of each of five Common Terminology Criteria for Adverse Events
(CTCAE) graded urinary toxicities was assessed at each follow-up visit. Medication usage
was documented at each visit. Patient-reported urinary symptoms were assessed using
the American Urological Association (AUA) symptom score and the Expanded Prostate Can-
cer Index Composite (EPIC)-26 at 1, 3, 6, 9, 12, 18, and 24 months. Late urinary symptom
flare was defined as an increase in the AUA symptom score of ≥5 points above baseline
with a degree of severity in the moderate to severe range (AUA symptom score ≥15).
The relationship between the occurrence of flare and pre-treatment characteristics were
examined.
Results: For all patients, the AUA symptom score spiked transiently at 1 month post-SBRT.
Of the 216 patients, 29 (13.4%) experienced a second transient increase in the AUA symp-
tom score that met the criteria for late urinary symptom flare. Among flare patients, the
median age was 66 years compared to 70 for those without flare (p=0.007). In patients
who experienced flare, CTCAE urinary toxicities including dysuria, frequency/urgency, and
retention peaked at 9–18 months, and alpha-antagonist utilization increased at 1 month
post-treatment, rose sharply at 12 months post-treatment, and peaked at 18 months (85%)
before decreasing at 24 months.The EPIC urinary summary score of flare patients declined
transiently at 1 month and experienced a second, more protracted decline between 6 and
18 months before returning to near baseline at 2-year post-SBRT. Statistically and clinically
significant increases in patient-reported frequency, weak stream, and dysuria were seen
at 12 months post-SBRT. Among flare patients, 42.9% felt that urination was a moderate
to big problem at 12 months following SBRT.
Conclusion: In this study, we characterize late urinary symptom flare following SBRT. Late
urinary symptom flare is a constellation of symptoms including urinary frequency/urgency,
weak stream, and dysuria that transiently occurs 6–18 months post-SBRT. Provision of
appropriate anticipatory counseling and the maintenance of prophylactic alpha-antagonists
may limit the bother associated with this syndrome.
Keywords: prostate cancer, SBRT, CyberKnife, EPIC, AUA symptom score, genitourinary toxicity, late urinary
symptom flare, bother
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INTRODUCTION
Due to unavoidable dose to the bladder neck and prostatic ure-
thra, genitourinary (GU) toxicities are common following prostate
cancer radiotherapy (1, 2). After external beam radiation therapy,
incidence of late GU toxicity (≥grade 2) ranges from 10 to 30%
(3–5). Previous studies have recognized older age (6), higher radi-
ation dose (5), and prior transurethral resection of the prostate
(TURP) (7) as risk factors for late GU toxicity following external
beam radiotherapy. GU toxicities are rarely an isolated finding,
occurring more commonly as a complex of lower urinary tract
symptoms (LUTS) (8). Recent data suggest that many of these tox-
icities may resolve with time (9) and analysis of actuarial incidence
may over-estimate their clinical significance (10).
Patient responses to validated questionnaires may better define
the longitudinal pattern of GU toxicity following radiother-
apy compared with physician-reported data (11). Late uri-
nary symptom flare was first described when urinary symptom
questionnaires were administered to patients following prostate
brachytherapy (12–14) and later confirmed by others (15, 16).
Younger age at time of implantation was the only pre-treatment
characteristic consistently associated with an increased risk of flare.
A case of late urinary symptom flare following stereotactic body
radiation therapy (SBRT) was first reported by Suy et al. (17). It
occurred 1-year post-SBRT and the patient eventually underwent
a transurethral resection of prostate tissue (TURP). Microscopic
evaluation of the TURP specimen suggested an inflammatory
process (17). Subsequently, we described a series of patients
experiencing post-SBRT late urinary toxicity, which resolved
with conservative treatment such as alpha-blockers and/or brief
steroid tapers (8). Endoscopic evaluation of these patients revealed
bladder neck/urethral hyperemia suggestive of cystourethritis.
While acute GU toxicity post-SBRT is well characterized (8,
18–24), the late GU toxicity of SBRT has not been fully described.
Here, we characterize the clinical features of late urinary symp-
tom flare following SBRT, and recommend conservative symptom
management approaches that may alleviate bother and minimize
unnecessary interventions such as cystoscopy.
MATERIALS AND METHODS
PATIENT SELECTION
Patients eligible for study inclusion had histologically confirmed,
clinically localized adenocarcinoma of the prostate treated per our
institutional protocol. Patients eligible for inclusion in this study
had a prostate-specific antigen (PSA) <40 ng/ml, clinical stage
T1c–T2c, and a Gleason score of ≤8. Exclusion criteria included
clinically involved lymph nodes on imaging, distant metastases on
bone scan; prior pelvic radiotherapy and/or prior radical prostate
surgery. Institutional IRB approval was obtained for retrospective
review of data that was prospectively collected in our institutional
database.
TREATMENT PLANNING AND DELIVERY
Stereotactic body radiation therapy treatment planning and deliv-
ery were conducted as previously described (25, 26). Briefly,
gold fiducials were placed into the prostate. Fused CT and MR
images were used for treatment planning. The clinical target
volume (CTV) included the prostate and the proximal seminal
vesicles. The planning target volume (PTV) equaled the CTV
expanded 3 mm posteriorly and 5 mm in all other dimensions.
The prescription dose was 35–36.25 Gy to the PTV delivered in
five fractions of 7–7.25 Gy over 1–2 weeks (27). The prescription
isodose line was limited to ≥75%. The bladder and membra-
nous urethra were contoured and evaluated with dose–volume
histogram analysis during treatment planning using Multiplan
(Accuray Inc., Sunnyvale, CA, USA) inverse treatment planning.
Critical structure dose constraints were as previously described
(26). To minimize the risk of local recurrence, no attempt was
made to limit the dose to the prostatic urethra. Target position
was verified during treatment using paired, orthogonal X-ray
images (25, 28).
FOLLOW-UP AND STATISTICAL ANALYSIS
Prostate-specific antigen levels were obtained before treatment,
1 month after the completion of SBRT, and during routine follow-
up visits every 3 months for the first year and every 6 months
for the second year of follow-up. All medications, including
alpha-antagonists, corticosteroids, non-steroidal antiinflamma-
tory drugs (NSAIDs), and urethral analgesics were documented
at each visit. Toxicity was assessed prospectively at follow-up visits
using the National Cancer Institute (NCI) Common Terminology
Criteria for Adverse Events (CTCAE) version 3.0. Patient-reported
outcomes were assessed pre-treatment and at follow-up visits
using the American Urological Association (AUA) symptom score
(29) and the Expanded Prostate Cancer Index Composite (EPIC)
short form (30).
Student’s t -test was used to assess differences in ongoing PSA
levels. Wilcoxon signed rank test and Mann–Whitney U test were
used to analyze the quality of life scores in comparison to baseline.
Sample medians and ranges were used to describe PSA levels. A
clinically significant urinary flare was prospectively defined as an
AUA symptom score≥15 with an increase of≥5 points above base-
line (15, 16). Based upon published results, a benign PSA bounce
was defined as a PSA rise of 0.2 ng/ml or more above its previous
nadir with a subsequent decline to that nadir or lower (31). To
statistically compare changes between time points, the levels of
responses were assigned a score and the significance of the mean
changes in the scores was assessed by paired t-test. EPIC scores
for the urinary domain and its individual questions range from
0 to 100 with lower values representing worsening urinary symp-
toms. The minimally important difference (MID) in EPIC score
was defined as a change of one-half standard deviation (SD) from
the baseline (32).
The impact of baseline patient characteristics on the incidence
of late urinary symptom flare was evaluated by univariate and
multivariate analyses. Univariate analysis of variance (ANOVA)
was used to detect significant relationship between patient char-
acteristics and urinary symptom flare. In multivariate analysis,
stepwise ordinal logistic regression modeling was used to deter-
mine independent factors predicting late urinary symptom flare.
The baseline patient characteristics that were included as vari-
ables in the univariate and multivariate analyses included age,
race, D’Amico Risk Group, Gleason score, T-Stage, prostate vol-
ume, PSA, testosterone level, baseline AUA symptom score, alpha-
antagonist usage, baseline EPIC urinary summary score, partner
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status, work status, Charlson comorbidity index, prior procedure
for benign prostatic hyperplasia (BPH), and pre-treatment andro-
gen deprivation therapy (ADT). All tests were two-tailed, and a
p-value <0.05 was considered significant. IBM® SPSS version 21
and MedCalc® version 12.6.1.0 were used to perform the statistical
analyses.
RESULTS
From August 2008 to August 2011, 216 patients with clinically
localized prostate adenocarcinoma were treated per our institu-
tional SBRT monotherapy protocol. The patients were followed for
a minimum of 24 months following SBRT. The median patient age
was 69 years (48–90 years) (Table 1). The percentage of patients
self-identified as white was 56.5 and 37.5% as black. Comorbidities
were common. The median prostate volume was 38 cc (11.6–
138.7 cc) and 8.8% had prior procedures for BPH. There were
38.4% low-risk patients, 51.4% patients were intermediate-risk,
and 10.2% patients were high-risk. Twenty-nine patients (13.4%)
also received ADT. A dose of 36.25 Gy delivered in five 7.25 Gy
fractions was used for 87.5% of patients.
The mean AUA symptom score increased transiently at 1 month
post-SBRT and returned to near baseline by 3 months post-SBRT
(Figure 1A). This acute increase was both statistically (p< 0.0001)
and clinically significant (MID= 2.99). A second late protracted
increase occurred between 9 and 18 months (Figure 1A). Transient
late urinary symptom flare (occurring ≥6 months after complet-
ing treatment) occurred in 13.4% of the patients (Figure 1B).
The median flare magnitude was 13 and the median time to flare
was 9 months (range, 6–18 months) (Figure 1C). The mean AUA
score reduced to below baseline at 2 years post-SBRT. Among flare
patients, the median age was 66 years compared to 70 for those
without flare (p= 0.007) (Table 2). No other baseline patient
characteristics were significantly associated with flare following
SBRT.
A PSA bounce of 0.2 ng/ml occurred in 30.1% of the study
group of 216 patients. A total of 9/29 patients (31.0%) of the
Table 1 | Patient demographics and characteristics.
Total (N =216) No flare (N =187) Flare (N =29)
Age (years) Median 69 (48–90) years/old Median 70 (49–90) years/old Median 66 (48–77) years/old
Race White 122 (56.5%) 109 (58.3%) 13 (44.8%)
Black 81 (37.5%) 65 (34.8%) 16 (55.2%)
Other 13 (6.0%) 13 (7.0%) 0 (0%)
Partner status Partnered 162 (75.0%) 138 (73.8%) 24 (82.8%)
Not partnered 54 (25%) 49 (26.2%) 5 (17.2%)
Work status Work 99 (45.8%) 87 (46.5%) 12 (41.4%)
Not employed 117 (54.2%) 100 (53.5%) 17 (58.6%)
Charlson comorbidity index (CCI) CCI=0 146 (64.6%) 127 (67.9%) 19 (65.5%)
CCI=1 51 (23.6%) 44 (23.5%) 7 (24.1%)
CCI≥2 19 (8.8%) 16 (8.6%) 3 (10.3%)
T-stage T1c 160 (74.1%) 139 (74.3%) 21 (72.4%)
T2a 29 (13.4%) 25 (13.4%) 4 (13.8%)
T2b 20 (9.3%) 17 (9.1%) 3 (10.3%)
T2c 7 (3.2%) 6 (3.2%) 1 (3.4%)
Gleason 6 97 (44.9%) 83 (44.4%) 14 (48.3%)
7 109 (50.5%) 94 (50.3%) 15 (51.7%)
8 10 (4.6%) 10 (5.3%) 0 (0%)
D’Amico risk groups Low 83 (38.4%) 71 (38.0%) 12 (41.4%)
Intermediate 111 (51.4%) 95 (50.8%) 16 (55.2%)
High 22 (10.2%) 21 (11.2%) 1 (3.4%)
Prostate volume (cc) Median 38 (11.6–138.7) Median 37.6 (11.6–108) Median 39.5 (13.8–138.7)
PSA (ng/ml) Median 5.8 (0.2–32.5) Median 5.8 (0.2–32.5) Median 5.7 (1.3–17.5)
Testosterone (ng/dL) Median 302.5 (20–1149) 285.5 (20–1149) 342 (40–692)
AUA score Median 7.5 (0–33) Median 8 (0–33) Median 7 (1–17)
EPIC urinary domain Median 88.9 (40.8–97.2) Median 88.9 (40.8–97.2) Median 94.4 (60.2–97.2)
α1A Antagonist usage 62 (28.7%) 54 (28.9%) 8 (27.6%)
Procedures for BPH 19 (8.8%) 18 (9.6%) 1 (3.5%)
ADT With ADT 29 (13.4%) 26 (13.9%) 3 (10.3%)
SBRT dose (Gy) 35 27 (12.5%) 23 (12.3%) 4 (13.8%)
36.25 189 (87.5%) 164 (87.7%) 25 (86.2%)
PSA, prostate-specific antigen; AUA, American Urological Association symptom score; EPIC, expanded prostate cancer index composite; BPH, benign prostate
hyperplasia; ADT, androgen deprivation therapy; SBRT, stereotactic body radiation therapy.
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FIGURE 1 | Late urinary symptom flare. (A) AUA symptom score at
baseline and following SBRT for prostate cancer. (B) Percentage of
patients with urinary symptom flare at each follow-up. (C) AUA
symptom score in patients with and without late urinary symptom
flare. Thresholds for clinically significant changes in scores (1/2
standard deviation above and below the baseline). AUA scores range
from 0 to 35 with higher values representing worsening urinary
symptoms.
flare patients experienced a PSA bounce compared with 56/187
(29.9%) of the non-flare patients who experienced a bounce. Of
the nine patients who experienced both a late urinary symptom
flare and benign PSA bounce, two experienced the bounce and
flare on the same follow-up evaluation. In three patients, the PSA
bounce occurred before the flare, and in four patients the bounce
occurred after the symptom flare.
For patients who experienced late urinary symptom flare,
the prevalence of each of five CTCAE-graded urinary toxici-
ties (hematuria, dysuria, incontinence, frequency, urgency, and
retention) during the first 2 years of follow-up is illustrated
in Table 3. Dysuria, urinary frequency/urgency, and retention
were the most commonly experienced late toxicities. At baseline
and each follow-up, usage of medication for urinary symptoms
was assessed (Table 4; Figure 2). At baseline, 31% of patients
reported using alpha-antagonists; this increased at 1 month post-
treatment, rose sharply at 12 months post-treatment, and peaked
at 18 months (85.2%) before decreasing at 24 months. Similarly,
anti-inflammatory and urethral analgesic use peaked at 12 and
18 months, respectively.
The declines in the EPIC urinary scores paralleled the increases
in the AUA symptom scores. The EPIC urinary summary score
declined transiently at 1 month post-SBRT and returned to
near baseline by 3 months post-SBRT (Figure 3A). This acute
decline was both statistically (p< 0.0001) and clinically significant
(MID= 6.48). A second late, protracted decline occurred between
9 and 18 months (Figure 3A). Transient late declines in the EPIC
urinary summary domain were occurred almost exclusively in
patients who experienced late urinary symptom flare (Figure 3B).
Statistically and clinically significant increases in patient-reported
frequency, weak stream, and dysuria were seen in flare patients
at 12 months post-SBRT (Figure 4). The EPIC urinary summary
score returned to near baseline by 2 years post-SBRT (Figures 3A,B
and 4).
At baseline, 9.3% of the patients felt that urination was a moder-
ate to big problem (Table 5). The mean EPIC urinary bother score
was 78.2 at baseline (Figure 5A). Urinary bother increased follow-
ing treatment with the mean score decreasing to 66.4 at 1 month
post-treatment (p< 0.0001) (Figure 5A). However, only 17.5%
of patients felt that urination was a moderate to big problem at
1 month following treatment (Table 5). Although urinary bother
declined quickly, a second late increase in urinary bother was
observed with the mean urinary bother score decreasing to 70.8 at
12 months (p= 0.009) (Figure 5A). Transient late declines in the
EPIC urinary bother score were more common in patients who
experienced late urinary symptom flare (Figure 5B). At 12 months
post-treatment, 42.9% of the flare patients felt that urination was a
moderate to big problem (Table 5). By 2 years following SBRT, uri-
nary bother returned to near baseline in both flare and non-flare
patients (Figure 5B).
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DISCUSSION
While conventionally fractionated intensity-modulated radiother-
apy (IMRT) and brachytherapy remain the most commonly
used radiation therapy modalities for clinically localized prostate
cancer, SBRT is increasingly utilized as primary treatment for low
Table 2 | Impact of baseline patient characteristics on the incidence of




D’Amico risk groups 0.381
Gleason score (6, 7, ≥8) 0.453





α1A antagonist usage 0.975
Initial EPIC urinary domain 0.166
Partner status 0.812
Work status 0.599
Charlson comorbidity index 0.794
Procedure for BPH 0.212
Androgen deprivation therapy 0.282
*Significant in multivariate analysis; † significant in univariate analysis.
PSA, prostate-specific antigen; AUA, American Urological Association urinary
symptom score; EPIC, expanded prostate cancer index composite; BPH, benign
prostate hypertrophy.
to intermediate-risk disease. Data from several single-institution
series (8, 20, 22, 33), multi-institutional phase I study (21), and
a multi-institutional registry (23, 24) suggest SBRT offers high
rates of biochemical control and low rates of grade 3 and higher
toxicities, comparable with conventionally fractionated IMRT
and brachytherapy. The maturation of these data is reflected
in ASTRO’s recent statement that SBRT can be “considered an
appropriate alternative for select patients with low to intermediate-
risk disease” (ASTRO Model Policies, 2012, https://www.astro.org/
Practice-Management/Reimbursement/Model-Policies.aspx). As
utilization of SBRT for prostate cancer will likely increase in com-
ing years, it is imperative to understand its impact on patients’
quality of life.
Some studies have suggested an increased incidence of late
GU toxicities following hypofractionated radiation therapy when
compared to conventionally fractionated treatment (34–36). Our
previous study showed a 30% incidence of late grade 2 GU toxic-
ities in the first 2 years following prostate SBRT (8). However, the
majority of these patients experienced resolution of their GU tox-
icities with time. Reporting toxicities as actuarial incidence might
overstate the significance of such problems (10, 37). In our opin-
ion, prevalence better reflects the impact of a given toxicity on a
patient’s quality of life, and should be the standard approach for
reporting toxicities.
Our analysis of the impact of baseline patient characteris-
tics on the incidence of late urinary symptom flare revealed
that young age was the only factor associated with an increased
risk of developing flare. The association with age has been pre-
viously been seen with late urinary symptom flare following
brachytherapy (14). To date, no mechanistic rationale has been
determined. Surprisingly, pre-treatment urinary function was not
significantly associated with flare in this study. Nor could we
Table 3 | Prevalence of CTCAE-graded urinary toxicities in flare patients following SBRT for prostate cancer.
Toxicity Follow-up (months) 1 3 6 9 12 18 24
Grade
Hematuria 0 92.6% 100.0% 96.2% 85.7% 93.1% 89.7% 96.4%
1 7.4% 0.0% 0.0% 10.7% 6.9% 10.3% 3.6%
2 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
3 0.0% 0.0% 3.8% 3.6% 0.0% 0.0% 0.0%
Dysuria 0 74.1% 85.2% 80.8% 75.0% 79.3% 82.8% 96.4%
1 25.9% 14.8% 19.2% 25.0% 20.7% 13.8% 3.6%
2 0.0% 0.0% 0.0% 0.0% 0.0% 3.4% 0.0%
Incontinence 0 77.8% 81.5% 76.9% 57.1% 72.4% 62.1% 82.1%
1 22.2% 18.5% 23.1% 39.3% 27.6% 37.9% 14.3%
2 0.0% 0.0% 0.0% 3.6% 0.0% 0.0% 3.6%
Urinary frequency/urgency 0 14.3% 44.4% 34.6% 25.0% 24.1% 41.4% 57.1%
1 75.0% 51.9% 61.5% 60.7% 58.6% 48.3% 42.9%
2 10.7% 3.7% 3.8% 14.3% 17.2% 10.3% 0.0%
Retention 0 37.0% 51.9% 42.3% 46.4% 41.4% 17.2% 46.4%
1 7.4% 22.2% 30.8% 17.9% 3.4% 17.2% 17.9%
2 55.6% 25.9% 26.9% 35.7% 55.2% 65.5% 35.7%
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Table 4 | Percent of flare patients utilized medications for urinary symptom relief at baseline and following SBRT for prostate cancer.
Start 1 3 6 9 12 18 24
α1A Inhibitor (%) 31.03 77.78 35.71 34.62 42.86 71.43 85.19 46.15
Anti-inflammatory (%) 0.00 7.41 3.57 3.85 14.29 17.86 3.70 0.00
Urethral analgesics (%) 0.00 0.00 0.00 0.00 3.57 3.57 3.70 0.00
FIGURE 2 | Medication utilization for urinary symptom relief by flare patients at baseline and following SBRT for prostate cancer.
FIGURE 3 | EPIC urinary summary domain scores. (A) EPIC urinary summary domain scores at baseline and following SBRT for prostate cancer. (B) EPIC
urinary summary domain scores in patients with and without late urinary symptom flare. Thresholds for clinically significant changes in scores (1/2 standard
deviation above and below the baseline) are marked with dashed lines. EPIC scores range from 0 to 100 with higher values representing a more favorable
health-related QOL.
establish a relationship between the severity of acute urinary symp-
toms and the incidence of late urinary symptom flare (data not
shown) (38).
Endoscopic evaluation of these patients suggests that these
symptoms may be caused by radiation-induced cystourethritis.
An inflammatory etiology is supported by late urinary symptom
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FIGURE 4 | Spider plots of individual EPIC urinary symptom scores at
baseline and following SBRT for prostate cancer. Dripping-question 4A of
the EPIC-26; dysuria-question 4B of the EPIC-26; hematuria-question 4C of
the EPIC-26; weak stream or incomplete emptying-question 4D of the
EPIC-26; and frequency-question 4E of the EPIC-26. EPIC scores range from
0 to 100 with higher values representing a more favorable health-related QOL.
Changes in scores that are both statistically and clinically significant are
marked with an asterisk (*).
Table 5 | Urinary bother in patients with and without late urinary symptom flare following SBRT for prostate cancer (patient-reported
responses to question 5 of the EPIC-26).
Start 1 Month 3 Months 6 Months 9 Months 12 Months 18 Months 24 Months
ALL PATIENTS
N 214 211 208 198 197 196 182 196
No problem (%) 46.3 24.6 40.9 42.9 40.1 35.7 44.5 45.4
Very small–small problem (%) 44.4 57.8 50.5 48.0 44.2 49.5 41.8 45.9
Moderate–big problem (%) 9.3 17.5 8.7 9.1 15.7 14.8 13.7 8.7
p-Value <0.0001* 0.9201 0.7601 0.0777 0.0086* 0.4353 0.7329
PATIENTS WITHOUT FLARE
N 185 184 180 172 169 168 155 170
No problem (%) 43.8 24.5 42.2 44.8 43.2 38.1 46.5 45.9
Very small–small problem (%) 47.6 58.2 48.9 46.5 43.2 51.8 41.3 45.9
Moderate–big problem (%) 8.6 17.4 8.9 8.7 13.6 10.1 12.3 8.2
p-Value <0.0001* 0.7298 0.9282 0.5778 0.3185 0.6496 0.3608
PATIENTS WITH FLARE
N 29 27 28 26 28 28 27 26
No problem (%) 62.1 25.9 32.1 30.8 21.4 21.4 33.3 42.3
Very small–small problem (%) 24.1 55.6 60.7 57.7 50.0 35.7 44.4 46.2
Moderate–big problem (%) 13.8 18.5 7.1 11.5 28.6 42.9 22.2 11.5
p-Value 0.0483* 0.5614 0.4307 0.0056* 0.0008* 0.0737 0.3028
*Changes in survey scores that are both statistically and clinically significant.
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FIGURE 5 | EPIC urinary bother scores. (A) EPIC urinary bother scores at
baseline and following SBRT for prostate cancer. (B) EPIC urinary bother
scores in patients with and without late urinary symptom flare. Thresholds for
clinically significant changes in scores (1/2 standard deviation above and
below the baseline) are marked with dashed lines. EPIC scores range from 0
to 100 with higher values representing a more favorable health-related QOL.
flare’s delayed occurrence and rapid symptomatic response to
oral steroids, not unlike post-radiation pneumonitis (39, 40).
Radiation-induced inflammation is known to be dependent on
radiation fractionation and the volume of the target organ irra-
diated (41, 42). Future studies should evaluate the impact of
treatment factors (such as bladder neck/urethral dose) on the
incidence of late urinary symptom flare (43). Interestingly, there
was no temporal relationship between late urinary symptom flare
and benign PSA bounces, suggesting a non-inflammatory nature
for post-SBRT PSA bounces (14).
Similar to BPH-associated LUTS, patients with late urinary
symptom flare present with obstructive and irritative voiding
symptoms. Alpha-blockers have been shown to improve urinary
flow and acute urinary symptoms following prostate radiother-
apy (44, 45). In this series, most flare patients responded to
alpha-antagonists. For those that did not respond adequately,
we initiated a short oral corticosteroid taper (dexamethasome
4 mg daily for 1 week followed by 2 mg for 1 week, then discon-
tinue) to reduce inflammation. With these conservative medical
approaches, the majority of patients with urinary symptom flare
recover to near baseline without the need for invasive proce-
dures. Only a few patients required urethral anesthetics for per-
sistent dysuria. Over the course of longer follow-up, we have not
observed flare recurrences beyond 2 years since treatment (data
not shown).
Prophylactic alpha-blockers have been shown to reduce uri-
nary morbidity following prostate brachytherapy (46, 47). To
maximize patient comfort, it is currently our institutional pol-
icy to initiate prophylactic alpha-antagonist use prior to initiating
treatment. Patients are encouraged to continue alpha-antagonist
usage until they return to their baseline urinary status and to
reinitiate alpha-antagonists with any worsening of their urinary
function.
We analyzed quality of life questionnaires to determine the
degree of bother experienced by patients with late urinary symp-
tom flare. Our results suggest that late urinary flare was highly
bothersome to a significant percentage of the patients who expe-
rienced it. It is likely that these patients, not anticipating the
onset of late urinary symptoms following a transient period
of acute symptoms and a symptom-free interval, were partic-
ularly sensitive to perceived changes in their urinary status as
they progressed further from the completion of SBRT (48).
Clinicians should anticipate the possibility of late urinary symp-
toms and communicate to patients that a late transient flare
may occur; this will better prepare patients for the onset of
symptoms and potentially mitigate the perceived severity of the
flare (48).
CONCLUSION
Our data provide compelling evidence for a clinical syndrome
of transient late-onset urinary symptoms associated with SBRT
for localized prostate cancer. The majority of flares occurs at 9–
18 months post-SBRT and resolve by 24 months after treatment.
Currently, it is difficult to predict which patients are at the high-
est risk of late urinary symptom flare. Provision of appropriate
anticipatory counseling for all patients prior to treatment and
utilization of alpha-antagonists may limit the need for invasive
interventions.
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